Catalog No.
Product Name
Application
Product Information
Citations
-
PA endonuclease Inhibitor
L-742001 hydrochloride is an inhibitor of the influenza virus PA endonuclease, specifically targeting the viral RNA polymerase complex. It demonstrates an effective EC90 of 4.3 μM for vRNP activity in HEK293T cells. This compound is valuable for research applications focused on antiviral drug development and understanding viral replication mechanisms. -
H1N1 Inhibitor
CBS1117 is a potent inhibitor of the H1N1 influenza A virus, exhibiting an IC50 of 70 nM. It specifically targets the hemagglutinin (HA) protein, disrupting the viral entry process by interfering with HA-mediated fusion. This compound is valuable for research applications focused on understanding influenza virus entry mechanisms and developing antiviral strategies. -
Cap-dependent Endonuclease Inhibitor
Pixavir marboxilo is a potent orally active cap-dependent endonuclease inhibitor that targets the viral polymerase complex. This compound is primarily utilized in influenza research to investigate viral replication mechanisms and evaluate potential therapeutic strategies. Its high efficacy makes it a valuable tool for studying the pathogenesis of influenza and developing antiviral treatments. -
Influenza A Virus Inhibitor
Influenza A virus-IN-1 is a dihydropyrrolidone derivative that serves as a potent inhibitor of various subtypes of influenza A virus (IAV), exhibiting IC50 values ranging from 3.11 μM to 7.13 μM. This compound effectively inhibits IAV replication and enhances the expression of key antiviral cytokines, including IFN-β, as well as the antiviral protein MxA. Its mechanisms make it a valuable tool for research in antiviral drug development and the study of host immune responses to viral infections. -
Anti-Influenza Agent
Anti-Influenza Agent 11 (compound L08) is a potent inhibitor of the Influenza virus, targeting viral replication and entry. This compound exhibits significant antiviral activity, making it a valuable tool in the study of influenza virus infections. It is essential for research focused on developing effective therapies and understanding the mechanisms underlying viral pathogenesis. -
NA Inhibitor
7,3',4'-Trihydroxy-3-benzyl-2H-chromene is a reversible noncompetitive neuraminidase (NA) inhibitor with significant antiviral activity. It demonstrates potent inhibitory effects against influenza virus strains, with IC50 values of 34.6 µM for H1N1, 39.5 µM for H3N2, and 50.5 µM for H9N2. This compound, derived from the dried heartwood of Caesalpinia sappan L., serves as a valuable reagent for research applications focusing on influenza virus inhibition and related studies in virology. -
Glycoprotein
Influenza HA (307-319) is a 13 amino acid fragment of the hemagglutinin glycoprotein, spanning residues 307 to 319. This peptide plays a crucial role in the binding of the influenza virus to host cell receptors, making it essential for viral entry and infection. It is commonly utilized in research applications related to vaccine development, antibody generation, and the study of immune responses against influenza viruses. -
Anti-virus Reagent
Triperiden is an antiviral reagent that inhibits influenza virus replication by targeting the haemagglutinin of fowl plague virus (FPV). Its primary mechanism involves preventing the conformational change in haemagglutinin at acidic pH, thereby interfering with viral entry and propagation. Additionally, Triperiden exhibits anticholinergic properties and is used as a treatment for Parkinson's disease. This dual activity makes it valuable for both antiviral research and studying neurological conditions. -
Neuraminidase Inhibitor
AV-5080 is an orally active neuraminidase inhibitor that targets the enzyme involved in the life cycle of influenza viruses. By inhibiting neuraminidase, AV-5080 effectively reduces viral replication and spread, making it a valuable tool in the study of influenza A and B viruses. This compound is suitable for research applications aimed at understanding viral pathogenesis and developing antiviral strategies. -
Influenza Neuraminidase Enzymes Inhibitor
Ganoderic acid TR is an inhibitor of influenza neuraminidase enzymes (NAs), demonstrating significant antiviral activity. It exhibits IC50 values of 10.9 μM and 4.6 μM against H5N1 and H1N1 strains, respectively, making it a promising candidate for further research in influenza treatment. However, Ganoderic acid TR is associated with cytotoxicity and shows limited efficacy against Oseltamivir-resistant H1N1 and influenza B viruses. -
Influenza A Virus Inhibitor
MBX2546 is an inhibitor of the Influenza A virus, specifically targeting H1 and H3 Hemagglutinin with Kd values of 5.3 μM and greater than 100 μM, respectively. This compound demonstrates potential for antiviral research and therapeutic development aimed at combating Influenza A infections. Its selective mechanism of action makes it a valuable tool for studying hemagglutinin-mediated viral entry and host cell interactions. -
Influenza Virus Inhibitor
Amizon is an orally effective antiviral agent targeting the influenza virus. It inhibits viral replication and restricts RNA synthesis, while simultaneously reducing the mRNA expression of pro-inflammatory mediators such as COX-1, COX-2, NF-κB, TGF-β1, IL-1, and IL-6. Additionally, Amizon enhances the secretion and mRNA expression of the anti-inflammatory cytokine IL-10 and exhibits antioxidant properties, inhibiting the oxidative activity of macrophages. This compound is of interest in research focused on influenza and acute respiratory viral infections. -
Antiviral Agent
Ingavirin is an antiviral agent that targets various human respiratory viruses, demonstrating broad-spectrum efficacy against influenza virus A, human parainfluenza virus, and human adenovirus. It is characterized by its significant antiviral activity without observed toxicity in murine models at doses up to 3000 mg/kg. Ingavirin is applicable in research related to viral infections and therapeutic development for respiratory diseases. -
Influenza Virus Nucleoprotein Epitope
CEF7 is an HLA-B*08 restricted epitope derived from the nucleoprotein (NP) of the influenza virus, specifically from residues 380-388. This peptide plays a critical role as an adapter molecule facilitating interactions between the virus and host cellular mechanisms. CEF7 is utilized in research applications focused on immunology and vaccine development, particularly in elucidating T cell responses to influenza virus infections. -
Cap-dependent Endonuclease Inhibitor
Cap-dependent endonuclease-IN-6 is a potent inhibitor of cap-dependent endonuclease (CEN), a critical enzyme required for the replication of certain viruses, including influenza. This compound exhibits substantial antiviral activity, demonstrating an effective EC50 of 38.21 nM against the influenza virus. It serves as a valuable tool for researchers investigating viral mechanisms and developing antiviral therapies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-20 is an inhibitor of cap-dependent endonuclease (CEN), targeting the viral replication process. It exhibits antiviral activity against the influenza virus A/Hanfang/359/95 (H3N2), with an IC50 of 4.82 μM. This compound is useful for research in virology, particularly in the study of influenza virus mechanisms and the development of antiviral therapeutics. -
Influenza Virus Growth Inhibitor
BMY-27709 is an influenza virus growth inhibitor that primarily targets hemagglutinin proteins. It demonstrates significant antiviral activity with an IC50 value of 3-8 μM against the A/WSN/33 strain. BMY-27709 effectively inhibits the growth of H1 and H2 subtype viruses early in the infection process, making it a valuable tool for research into influenza virus pathogenesis and therapeutic development. However, it does not inhibit H3 subtype viruses or influenza B/Lee/40 strains. -
CEN Inhibitor
Cap-dependent endonuclease-IN-9 is a selective inhibitor of cap-dependent endonuclease (CEN), demonstrating significant efficacy against influenza viruses. This compound exhibits low cytotoxicity and favorable pharmacokinetic and pharmacodynamic properties in vivo. Cap-dependent endonuclease-IN-9 effectively inhibits the RNA polymerase activity of A viruses, making it a valuable tool for research in antiviral therapeutics and molecular biology studies. -
Antiinfluenzal Agent
(−)-Rugulosin is a fungal metabolite that acts as an orally active anti-influenza agent. This compound exhibits significant antiviral activity against influenza viruses, making it valuable for research aimed at understanding viral pathogenesis and potential therapeutic strategies. Its efficacy in inhibiting viral replication supports further investigation into its mechanisms of action and potential applications in antiviral drug development. -
Endonuclease Inhibitor
Flutimide is a selective endonuclease inhibitor that targets the influenza virus. Demonstrating an IC50 value of 3 μM, Flutimide exhibits significant antiviral activity in cell culture assays. This compound is valuable for research focused on acute contagious respiratory diseases, particularly influenza, and can aid in the investigation of therapeutic strategies against viral infections. -
Influenza A Virus Inhibitor
3-epi-Dihydroscandenolide is a sesquiterpene lactone that serves as an inhibitor of influenza A virus. Isolated from the dried aerial parts of Mikania micrantha, this compound effectively inhibits the cytopathic effects induced by the virus. 3-epi-Dihydroscandenolide is valuable for research applications focused on influenza A and may aid in the development of antiviral strategies. -
Antiviral Agent
MI-1904 is a potent inhibitor of matriptase/TMPRSS2, showcasing significant antiviral activity against influenza viruses H1N1 and H9N2. By blocking the cleavage of surface glycoproteins, MI-1904 effectively prevents viral binding to host cell receptors, thereby inhibiting viral entry and replication. This compound is a valuable tool for research focused on virology and antiviral therapeutic development. -
A/M2 Inhibitor
3-Azaspiro[5.5]undecane hydrochloride is an inhibitor of the wild-type influenza A virus M2 ion channel. It demonstrates potent biological activity with an IC50 value of 1 μM, making it a valuable tool for studying influenza virus function and host-pathogen interactions. This compound is applicable in viral research and can aid in the development of antiviral strategies targeting M2. -
Hemagglutinin Inhibitor
Influenza virus-IN-5 is a potent inhibitor of influenza virus hemagglutinin (HA), demonstrating an EC50 of 1 nM against the influenza A/H3N2 strain. This compound is valuable for research applications focused on viral entry and infection mechanisms. Its high selectivity and efficacy make it an important tool for studying influenza virus pathogenesis and developing antiviral strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-26 is a selective inhibitor of cap-dependent endonuclease (CEN), exhibiting an IC50 of 286 nM. This compound demonstrates significant antiviral activity against various strains of influenza A and B, making it a valuable tool for research in antiviral therapy and mechanisms of viral replication. Its use may advance the understanding of CEN's role in viral RNA processing and contribute to the development of new antiviral strategies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN), primarily targeting influenza A virus. This compound demonstrates significant inhibitory activity, making it a valuable tool for studying the mechanisms of influenza virus infection. Researchers can utilize Cap-dependent endonuclease-IN-13 to explore viral replication pathways and evaluate potential therapeutic interventions. -
Influenza Virus Neuraminidase Inhibiotr
BCX-1898 is a cyclopentane derivative that functions as a selective inhibitor of influenza virus neuraminidase. It exhibits potent antiviral activity, with effective concentrations (EC50s) ranging from less than 0.01 to 21 μM against various strains of influenza A (H1N1, H3N2, H5N1) and influenza B viruses in MDCK cell cultures. Additionally, BCX-1898 demonstrates protective effects in mouse models of influenza, making it a valuable tool for research in antiviral drug development and the study of influenza virus pathogenesis. -
PAN Endonuclease Inhibitor
PAN endonuclease-IN-1 is a potent inhibitor of PAN endonuclease, showing Kd values of 277 μM, 384 μM, and 328 μM for wild-type, I38T, and E23K variants, respectively. Targeting the RNA-dependent RNA polymerase acidic N-terminal endonuclease, this compound plays a critical role in disrupting influenza viral replication. It is a valuable tool for studying antiviral strategies and the effects of PAN endonuclease inhibition on influenza virus biology. -
Conjugate of Zanamivir-Amantadine
Antiviral agent 80 is a conjugate of Zanamivir and Amantadine, functioning as a dual inhibitor targeting the influenza virus M2 ion channel and neuraminidase (NA). This compound demonstrates potent inhibitory effects against both wild-type and drug-resistant influenza neuraminidase mutants, with an IC50 value range of 1.50 nM to 120.4 nM. Antiviral agent 80 is valuable for research applications focused on influenza pathogenesis and therapeutic strategies. -
Influenza Virus Inhibitor
Influenza virus-IN-2 is a potent inhibitor of the influenza virus, demonstrating significant antiviral activity with an EC50 of 2.58 µM and a cytotoxicity threshold of CC50 at 150.85 µM. This compound exhibits concentration-dependent inhibition of PAN endonuclease, with an EC50 of 489.39 nM. Influenza virus-IN-2 is effective against influenza A virus, making it a valuable tool for research focused on antiviral drug development and the mechanisms of influenza virus replication. -
Neuraminidase Inhibitor
Ganoderic acid T-N is a triterpenoid compound that functions as a neuraminidase inhibitor, specifically targeting H5N1 and H1N1 influenza strains with IC50 values of 2.7 μM and 42 μM, respectively. In addition to its antiviral properties, Ganoderic acid T-N demonstrates cytotoxic effects against MCF7 cancer cells, exhibiting a CC50 value of 24.4 μM. This compound is relevant for research applications in virology and cancer biology, providing insights into influenza pathogenesis and potential therapeutic strategies. -
Influenza Viru Inhibitor
Tirfipiravir is a nucleoside analog with antiviral properties, primarily targeting influenza viruses. This compound exhibits potent activity against viral replication by inhibiting RNA polymerase, making it a valuable tool for research on viral infections. Tirfipiravir is particularly applicable in studies focusing on the mechanisms of antiviral resistance and developing therapeutic strategies against influenza. -
Neuraminidase Inhibitor
Influenza A virus-IN-4 is a potent neuraminidase inhibitor with significant antiviral activity against influenza A viruses. As an Oseltamivir derivative, it effectively impedes viral replication by blocking the enzymatic function of neuraminidase, thereby preventing the release of new viral particles. This compound is valuable for research focused on influenza virology and therapeutic intervention strategies. -
Antiinfluenza Agent
Amitivir is a thiadiazole derivative that serves as an anti-influenza agent with broad antiviral activity against orthomyxoviruses and paramyxoviruses. It demonstrates significant efficacy against both influenza A and B viruses, making it a valuable tool for research on influenza antiviral strategies and therapeutic development. This compound is suitable for studies related to viral infection mechanisms and the evaluation of antiviral efficacy. -
CEN Inhibitor
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN), targeting the enzymatic activity crucial for the replication of various viruses, including influenza. This compound demonstrates a strong inhibitory effect on RNA polymerase activity in A viruses, making it a valuable tool for virology research. Notably, Cap-dependent endonuclease-IN-2 exhibits lower cytotoxicity and favorable pharmacokinetic properties in vivo, supporting its potential as an effective antiviral agent for further investigation. -
Cap-dependent Endonuclease Inhibitor
Influenza virus-IN-7 is a potent cap-dependent endonuclease inhibitor designed for research into influenza viral infections. This compound exhibits oral bioavailability and can effectively modulate the viral lifecycle by hindering the endonuclease activity essential for viral RNA processing. Its application extends to studies focusing on influenza pathogenesis and the development of antiviral therapies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-5 is a selective inhibitor of cap-dependent endonuclease (CEN), a crucial enzyme in the lifecycle of the influenza virus. This compound demonstrates significant antiviral activity against influenza while exhibiting lower cytotoxicity compared to existing treatments. Additionally, Cap-dependent endonuclease-IN-5 shows improved pharmacokinetic and pharmacodynamic properties in vivo, making it a valuable tool for research on CEN-targeted antiviral therapies. -
CEN Inhibitor
Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). This pyridone polycyclic derivative is designed for research applications focusing on influenza, specifically targeting the viral replication process. Its inhibitory effects on CEN make it a valuable tool for studying the mechanisms of RNA transcription and development of antiviral strategies. -
Antiviral Agent
1,4-Epidioxybisabola-2,10-dien-9-one is an antiviral agent derived from Curcuma longa L., exhibiting significant activity against the influenza virus A/PR/8/34 (H1N1). It demonstrates an IC50 of 16.79 ± 4.03 μg/mL in the MDCK cell line, making it a valuable tool for antiviral research. Its unique chemical structure and mechanism of action may provide insights into the development of novel antiviral therapeutics. -
CEN Inhibitor
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN), crucial for the replication of influenza viruses. This compound specifically targets influenza A, demonstrating significant antiviral activity. It serves as a valuable tool for research focused on understanding influenza virus infection and developing therapeutic strategies against this pathogen. -
Diarylheptanoid
Antiviral agent 68 is a diarylheptanoid derived from Alpinia katsumadai. It exhibits weak inhibitory activity against the neuraminidase enzyme of influenza virus A/PR/8/34, with an IC50 value of 29.75 μM. This compound is of interest for researchers investigating antiviral mechanisms and the development of therapeutic strategies against influenza viruses. -
Neuraminidase (NA) Inhibitor
Neuraminidase-IN-10 is a highly potent inhibitor of neuraminidase (NA), exhibiting significant anti-influenza activity. It demonstrates inhibitory effects against H1N1, H5N1, and H5N8 strains with IC50 values of 2.6 nM, 5.1 nM, and 1.65 nM, respectively. This compound is valuable for research applications focusing on viral pathogenesis and therapeutic development for influenza infections. -
RSV Inhibitor
RSV-IN-3 is a dual inhibitor targeting respiratory syncytial virus (RSV) and influenza virus A (IAV). It demonstrates significant anti-RSV activity with an EC50 value of 32.70 μM. RSV-IN-3 can be utilized in research focused on viral pathogenesis and the development of antiviral therapeutics for respiratory viral infections. -
CEN Inhibitor
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN), which plays a critical role in viral RNA synthesis. This compound effectively inhibits multiple strains of the influenza virus while exhibiting lower cytotoxicity and favorable in vivo pharmacokinetic and pharmacodynamic profiles. Additionally, Cap-dependent endonuclease-IN-10 demonstrates enhanced hepatic microsomal stability, making it valuable for research applications focused on viral infections, including influenza A, B, and C. -
HA Inhibitor
RO5487624 is an orally active hemagglutinin (HA) inhibitor that targets the influenza H1N1 virus. It functions by disrupting HA conformational changes necessary for viral fusion in acidic environments, effectively preventing virus entry into host cells. In preclinical studies, RO5487624 has demonstrated protective effects in mice challenged with lethal doses of the influenza H1N1 virus, highlighting its potential applications in antiviral research and therapeutic development. -
Epitope
Influenza Matrix Protein (61-72) is a peptide fragment corresponding to amino acids 61-72 of the influenza virus matrix protein, functioning as a specific epitope. This peptide is capable of inducing a CD4+ T-cell response, making it a valuable tool for studying immune responses in influenza research. It can be utilized in the development of vaccines and therapeutic strategies aimed at enhancing T-cell-mediated immunity against influenza infections. -
RSV/IAV Inhibitor
RSV/IAV-IN-3 is a dual inhibitor targeting both respiratory syncytial virus (RSV) and influenza A virus (IAV) with reported EC50 values of 2.92 µM and 1.90 µM, respectively. This compound exhibits significant antiviral activity against H1N1 and H3N2 strains, achieving EC50 values of 3.25 µM and 1.50 µM in MDCK cells. Notably, RSV/IAV-IN-3 inhibits IAV infectivity and RNA-dependent RNA polymerase (RdRp) activity while effectively suppressing viral replication at the post-entry stage. Its influence on luciferase activity further emphasizes its potential in antiviral research applications. -
Diarylheptanoid Compound
Antiviral Agent 41 is a diarylheptanoid compound derived from Alpinia officinarum. This compound has demonstrated promising antiviral activity against the influenza virus in vitro, making it a valuable tool in the study of viral infections and the development of antiviral therapeutics. Researchers may utilize Antiviral Agent 41 in investigations aimed at understanding viral mechanics and evaluating potential antiviral agents. -
CEN Inhibitor
Cap-dependent endonuclease-IN-14 is a selective inhibitor of cap-dependent endonuclease (CEN), a key enzyme involved in the replication of influenza viruses. By disrupting the function of CEN, this compound effectively inhibits viral replication, making it a valuable tool for studying influenza virus infections. Its application extends to virology research focused on antiviral drug development and understanding the mechanisms of influenza pathogeneses. -
Anti-influenza Virus Agent
HAA-09 is a potent anti-influenza agent that targets the PB2_cap binding domain of the influenza polymerase complex. It exhibits strong inhibitory activity against influenza A virus, with an EC50 of 0.03 μM, and demonstrates polymerase inhibition with an IC50 of 0.06 ± 0.004 μM. HAA-09 effectively blocks viral replication while exhibiting minimal cytotoxicity, making it a valuable compound for research into antiviral therapies and mechanisms of influenza virus control.
